LEUVEN, Belgium, September 30, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that it has established a sponsored Level 1 American Depositary Receipt (ADR) program. Trading of the ADRs commences today on the US over the counter (OTC) market under the ticker TBGNY. ThromboGenics' ADRs are US dollar negotiable certificates with each ADR representing half of one ordinary share of the Company. J.P. Morgan has been appointed as the depositary bank for the ThromboGenics' ADR program. ADR effective date: September 30, 2013 Symbol: TBGNY Traded: OTC Ratio 2 ADRs: 1 Ordinary Share CUSIP: 886003 10 2 Local ISIN: BE0003846632 Country of incorporation:BelgiumIndustry: Biopharmaceutical Depositary: JPMorgan Chase Bank, N.A. Custodian: BNP Paribas, Belgium For questions related to the ThromboGenics ADR Program, please contact J.P. Morgan shareholder services: J.P. Morgan Depositary Bank 1 Chase Manhattan Plaza, Floor 58 New York, NY 10005 In the U.S.: (866) JPM-ADRS Outside the U.S.: (+1 866 576-2377) Or visit J.P. Morgan Depositary Receipts Services at http://www.adr.com. About ThromboGenics ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA ® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA ® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA ®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA ® for a number of new vitreoretinal indications. In Europe, JETREA ® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA ® in the UK, Germany, Denmark, Norway, Finland and Sweden. ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403.